5-formyl-4-methyl-1H-pyrrole-2-carboxylic acid (2-morpholin-4-yl-ethyl)-amide | 346600-26-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 5-formyl-4-methyl-1H-pyrrole-2-carboxylic acid (2-morpholin-4-yl-ethyl)-amide
• 英文别名: 5-formyl-4-methyl-N-[2-(morpholin-4-yl)ethyl]-1H-pyrrole-2-carboxamide；5-formyl-4-methyl-N-(2-morpholin-4-ylethyl)-1H-pyrrole-2-carboxamide
• CAS: 346600-26-8
• 化学式: C₁₃H₁₉N₃O₃
• 分子量: 265.312
• InChiKey: DFBWBLNIYHDIIY-UHFFFAOYSA-N

物化性质

• 沸点：
  468.7±45.0 °C(Predicted)
• 密度：
  1?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  74.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-formyl-4-methyl-1H-pyrrole-2-carboxylic acid (2-morpholin-4-yl-ethyl)-amide 在 三乙胺 作用下， 以 乙醇 、 乙二醇甲醚 为溶剂， 生成 Pyrrolo[2,3-d]pyrimidin-6-one deriv. 28d
  参考文献：
  名称：

  Rational design of 4,5-disubstituted-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-ones as a novel class of inhibitors of epidermal growth factor receptor (EGF-R) and Her2(p185erbB) tyrosine kinases

  摘要：

  A novel class of 4,5-disubstituted-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-ones has been discovered as potent and selective inhibitors of the EGF-R tyrosine kinase family. These compounds selectively inhibit EGF-R kinase activity at low nanomolar concentration and tyrosine autophosphorylation in cells expressing EGF-R or Her2 (p185(erbB)). Structure-activity relationships (SARs) for this class of compounds are presented. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00364-5
• 作为产物：
  描述：

  4-甲基-2-吡咯羧酸乙酯 在 氢氧化钾 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 三乙胺 、 三氯氧磷 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 5-formyl-4-methyl-1H-pyrrole-2-carboxylic acid (2-morpholin-4-yl-ethyl)-amide
  参考文献：
  名称：

  Rational design of 4,5-disubstituted-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-ones as a novel class of inhibitors of epidermal growth factor receptor (EGF-R) and Her2(p185erbB) tyrosine kinases

  摘要：

  A novel class of 4,5-disubstituted-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-ones has been discovered as potent and selective inhibitors of the EGF-R tyrosine kinase family. These compounds selectively inhibit EGF-R kinase activity at low nanomolar concentration and tyrosine autophosphorylation in cells expressing EGF-R or Her2 (p185(erbB)). Structure-activity relationships (SARs) for this class of compounds are presented. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00364-5

文献信息

• 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
  申请人：——

  公开号：US20020183319A1

  公开（公告）日：2002-12-05

  This invention relates to 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors. Particular 4-substituted 7-aza-indolin-2-ones disclosed herein are of Formula 1 1 and pharmaceutically acceptable salts, solvates, clathrates, and prodrugs thereof, wherein R 1 , R 2 , R 3 , R 4 , X, Y, and Z are defined herein. The invention fuirther relates to pharmaceutical compositions and dosage forms comprising compounds of Formula 1 and to methods of their use for the treatment and/or prevention of diseases such as, but not limited to, cancer.

  该发明涉及4-取代的7-氮杂吲哚-2-酮及其作为蛋白激酶抑制剂的用途。本文披露的特定4-取代的7-氮杂吲哚-2-酮属于第11式和其药学上可接受的盐、溶剂合物、包合物和前药，其中R1、R2、R3、R4、X、Y和Z在此定义。该发明还涉及包含第1式化合物的药物组合物和剂型，以及其用于治疗和/或预防癌症等疾病的方法。
• 4-Substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
  申请人：SUGEN, INC.

  公开号：US20040053924A1

  公开（公告）日：2004-03-18

  This invention relates to 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors. Particular 4-substituted 7-aza-indolin-2-ones disclosed herein are of Formula 1 1 and pharmaceutically acceptable salts, solvates, clathrates, and prodrugs thereof, wherein R 1 , R 2 , R 3 , R 4 , X, Y, and Z are defined herein. The invention further relates to pharmaceutical compositions and dosage forms comprising compounds of Formula 1 and to methods of their use for the treatment and/or prevention of diseases such as, but not limited to, cancer.

  本发明涉及4-取代的7-氮杂吲哚-2-酮及其作为蛋白激酶抑制剂的用途。本文披露的特定4-取代的7-氮杂吲哚-2-酮属于公式11和其药学上可接受的盐、溶剂合物、包合物和前药，其中R1、R2、R3、R4、X、Y和Z在此定义。本发明还涉及包含公式1化合物的制药组合物和剂型，以及其用于治疗和/或预防癌症等疾病的方法。
• 4-substituted 7-AZA-indolin-2-ones and their use as protein kinase inhibitors
  申请人：Liang Congxin

  公开号：US06908930B2

  公开（公告）日：2005-06-21

  This invention relates to 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors. Particular 4-substituted 7-aza-indolin-2-ones disclosed herein are of Formula 1 and pharmaceutically acceptable salts, solvates, clathrates, and prodrugs thereof, wherein R 1 , R 2 , R 3 , R 4 , X, Y, and Z are defined herein. The invention further relates to pharmaceutical compositions and dosage forms comprising compounds of Formula 1 and to methods of their use for the treatment and/or prevention of diseases such as, but not limited to, cancer.

  本发明涉及4-取代的7-氮杂吲哚-2-酮及其作为蛋白激酶抑制剂的用途。本文所披露的特定的4-取代的7-氮杂吲哚-2-酮为式1及其药学上可接受的盐、溶剂合物、包合物和前药，其中R1、R2、R3、R4、X、Y和Z在此定义。本发明还涉及包含式1化合物的制药组合物和剂型，以及其用于治疗和/或预防癌症等疾病的方法，但不限于此。
• Rational design of 4,5-disubstituted-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-ones as a novel class of inhibitors of epidermal growth factor receptor (EGF-R) and Her2(p185erbB) tyrosine kinases
  作者：Li Sun、Jean Cui、Congxin Liang、Yong Zhou、Asaad Nematalla、Xueyan Wang、Hui Chen、Cho Tang、James Wei

  DOI：10.1016/s0960-894x(02)00364-5

  日期：2002.8

  A novel class of 4,5-disubstituted-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-ones has been discovered as potent and selective inhibitors of the EGF-R tyrosine kinase family. These compounds selectively inhibit EGF-R kinase activity at low nanomolar concentration and tyrosine autophosphorylation in cells expressing EGF-R or Her2 (p185(erbB)). Structure-activity relationships (SARs) for this class of compounds are presented. (C) 2002 Elsevier Science Ltd. All rights reserved.